OrthoPediatrics (KIDS) Aktienübersicht
OrthoPediatrics Corp. ist ein Medizintechnikunternehmen, das anatomisch geeignete Implantate, Instrumente und spezielle Zahnspangen für Kinder mit orthopädischen Erkrankungen in den Vereinigten Staaten und international entwirft, entwickelt und vertreibt. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 2/6 |
| Künftiges Wachstum | 0/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 5/6 |
| Dividenden | 0/6 |
KIDS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
OrthoPediatrics Corp. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$20.33 |
| 52-Wochen-Hoch | US$23.70 |
| 52-Wochen-Tief | US$14.42 |
| Beta | 0.99 |
| 1 Monat Veränderung | 10.13% |
| 3 Monate Veränderung | 27.30% |
| 1 Jahr Veränderung | -7.13% |
| 3 Jahre Veränderung | -54.21% |
| 5 Jahre Veränderung | -65.21% |
| Veränderung seit IPO | 5.78% |
Aktuelle Nachrichten und Updates
Narrativ-Update • Jun 24
KIDS: Pediatric Orthopedic Execution And 2026 Guidance Will Drive Upside Potential
OrthoPediatrics’ analyst price target has shifted modestly, with a recent $1 upward move and $3 downward moves leaving the Street view recalibrated as analysts weigh updated assumptions on discount rates, profit margins, and future P/E expectations. Analyst Commentary Recent Street research on OrthoPediatrics reflects a mix of optimism and caution as analysts reassess their models, which has led to both upward and downward adjustments to the stock’s price target.Narrativ-Update • Jun 08
KIDS: 2026 Guidance Delivery Will Shape Upside From Pediatric Orthopedic Focus
Analysts have made a modest net reduction of $2 in their price targets for OrthoPediatrics, reflecting updated views on the stock that incorporate both more cautious and more optimistic research opinions. Analyst Commentary Recent research on OrthoPediatrics shows a mixed but measured stance, with one firm trimming its price target and another lifting theirs.Narrativ-Update • May 24
KIDS: 2026 Product Launches And Guidance Execution Will Drive Upside Potential
Narrative Update on OrthoPediatrics The updated analyst price target for OrthoPediatrics edges up from about $24.00 to roughly $24.67, as analysts factor in recent price target revisions across the Street and modest adjustments to long term growth, profitability, and future P/E assumptions. Analyst Commentary Recent Street commentary around OrthoPediatrics reflects a mix of optimism about the company’s long term opportunity and caution around execution and valuation, which together shape the modestly higher blended price target.
Narrativ-Update • May 07
KIDS: Cash Flow And 2026 Launches Will Offset More Cautious Long Range Assumptions
The analyst price target for OrthoPediatrics has been revised from $20 to $17 as analysts factor in slightly lower long range assumptions for revenue growth, profit margins, and future P/E, while still highlighting prior commentary around solid EBITDA, free cash flow, and contributions from upcoming product launches. Analyst Commentary Recent research shows a mix of views on OrthoPediatrics, with some analysts trimming expectations even as others highlight prior strength in EBITDA, free cash flow, and potential contributions from future product launches.Recent updates
Narrativ-Update • Jun 24
KIDS: Pediatric Orthopedic Execution And 2026 Guidance Will Drive Upside Potential
OrthoPediatrics’ analyst price target has shifted modestly, with a recent $1 upward move and $3 downward moves leaving the Street view recalibrated as analysts weigh updated assumptions on discount rates, profit margins, and future P/E expectations. Analyst Commentary Recent Street research on OrthoPediatrics reflects a mix of optimism and caution as analysts reassess their models, which has led to both upward and downward adjustments to the stock’s price target.Narrativ-Update • Jun 08
KIDS: 2026 Guidance Delivery Will Shape Upside From Pediatric Orthopedic Focus
Analysts have made a modest net reduction of $2 in their price targets for OrthoPediatrics, reflecting updated views on the stock that incorporate both more cautious and more optimistic research opinions. Analyst Commentary Recent research on OrthoPediatrics shows a mixed but measured stance, with one firm trimming its price target and another lifting theirs.Narrativ-Update • May 24
KIDS: 2026 Product Launches And Guidance Execution Will Drive Upside Potential
Narrative Update on OrthoPediatrics The updated analyst price target for OrthoPediatrics edges up from about $24.00 to roughly $24.67, as analysts factor in recent price target revisions across the Street and modest adjustments to long term growth, profitability, and future P/E assumptions. Analyst Commentary Recent Street commentary around OrthoPediatrics reflects a mix of optimism about the company’s long term opportunity and caution around execution and valuation, which together shape the modestly higher blended price target.Narrativ-Update • May 07
KIDS: Cash Flow And 2026 Launches Will Offset More Cautious Long Range Assumptions
The analyst price target for OrthoPediatrics has been revised from $20 to $17 as analysts factor in slightly lower long range assumptions for revenue growth, profit margins, and future P/E, while still highlighting prior commentary around solid EBITDA, free cash flow, and contributions from upcoming product launches. Analyst Commentary Recent research shows a mix of views on OrthoPediatrics, with some analysts trimming expectations even as others highlight prior strength in EBITDA, free cash flow, and potential contributions from future product launches.
Narrativ-Update • Apr 22
KIDS: Solid Cash Generation And 2026 Launches Will Support Higher Upside
Narrative Update on OrthoPediatrics The Street price targets for OrthoPediatrics have nudged higher, with moves such as Truist's shift to $20 from $19 and Stifel's to $22 from $20, as analysts point to solid Q4 EBITDA, better free cash flow, and expected contributions from new product launches, along with confidence in the company's long-range revenue outlook of 12%. Analyst Commentary Recent research updates highlight a cluster of positive shifts in sentiment around OrthoPediatrics, centered on solid Q4 execution and growing confidence in the company’s long term revenue framework.Narrativ-Update • Apr 07
KIDS: Solid Cash Flow And 2026 Launches Will Support Long Range Outlook
Analyst price targets for OrthoPediatrics have ticked higher, with recent moves such as Truist lifting its target to $20 and Stifel to $22. These changes reflect analyst views that solid Q4 EBITDA, free cash flow and potential contributions from future product launches support the company’s long range revenue outlook.Narrativ-Update • Mar 24
KIDS: Solid Cash Generation And 2026 Launches Are Expected To Drive Upside
Analyst price targets for OrthoPediatrics have moved higher by $1 to a range of $20 to $22. This reflects analyst views that solid recent EBITDA and free cash flow, along with expected contributions from new products in 2026, support the company's long range 12% revenue outlook and a slightly higher fair value estimate.Narrativ-Update • Mar 09
KIDS: Solid Cash Flow And 2026 Launches Will Shape Balanced Outlook
Narrative Update: OrthoPediatrics The analyst price target for OrthoPediatrics has moved from $19 to $20. This change reflects analysts' views that recent solid Q4 EBITDA and free cash flow, along with expectations for contributions from planned product launches and long-range revenue growth, support a modestly higher fair value and a slightly higher future P/E assumption.Narrativ-Update • Feb 22
KIDS: Execution On 2026 Revenue Guidance Will Support Upside Potential
Analysts have trimmed their price target on OrthoPediatrics slightly to $24.00 from $24.13, citing updated assumptions for revenue growth, profit margins, discount rate, and future P/E that remain broadly supportive of the positive view reflected in recent Street research. Analyst Commentary Recent Street commentary frames OrthoPediatrics as a higher risk, higher reward idea, where execution on growth plans and disciplined cost control are key to justifying the updated US$24.00 price target.Narrativ-Update • Feb 08
KIDS: Higher Margin Outlook Will Support Bullish Long Term Opportunity
Analysts have trimmed their price target on OrthoPediatrics by $3 to $19, citing updated assumptions for slightly slower revenue growth, a modestly higher discount rate, and a lower future P/E multiple, even though projected profit margins are set at a higher level. Analyst Commentary Even with higher projected profit margins in current models, some bearish analysts remain cautious on OrthoPediatrics.Narrativ-Update • Jan 25
KIDS: Revenue Visibility And Margin Progress Are Expected To Drive Long Term Upside
Analysts have lowered their price target on OrthoPediatrics, with one firm cutting its target to $26 from $42 as they factor in updated expectations for revenue growth and profitability, even as the company guides to revenue growth of over 12% over the next few years. Analyst Commentary Bullish analysts see the recent price target reset as more of a recalibration than a complete shift in sentiment.Narrativ-Update • Jan 11
KIDS: Reset Execution Expectations Should Support Upside From Revised Growth Outlook
Analysts have nudged their price target on OrthoPediatrics lower to about US$24.13 per share from roughly US$24.14, citing slightly reduced revenue growth and profit margin assumptions following recent quarterly results and updated company guidance around revenue growth of over 12% in the coming years. Analyst Commentary Analysts are parsing the latest update on OrthoPediatrics with a mix of optimism around growth and caution around execution and profitability.Narrativ-Update • Dec 24
KIDS: Core High Margin Segments Are Expected To Drive Long Term Upside
Analysts have reduced their price target on OrthoPediatrics from about $42 to roughly $33, citing lower long term revenue growth assumptions and a modestly higher discount rate, despite resilient margins and confidence in the company’s core high margin segments. Analyst Commentary Bullish analysts acknowledge that the recent price target reductions reflect tempered expectations for near term growth, but they continue to frame OrthoPediatrics as a long term execution story with attractive end market exposure.Narrativ-Update • Dec 10
KIDS: Reset Expectations Will Support Upside From Core High-Margin Franchise
Analysts trimmed their OrthoPediatrics price targets by roughly $6 to $10 per share across the Street, citing lowered revenue growth forecasts, below consensus Q3 results, and more conservative long term guidance, even as they maintained confidence in the company’s core, higher margin businesses. Analyst Commentary Street research following OrthoPediatrics' preliminary Q3 update reflects a mix of near term caution and longer term optimism, with price targets reset lower but most ratings remaining positive.Narrativ-Update • Nov 26
KIDS: Revenue Miss Expected To Set Up Double-Digit Upside Over The Next Year
Analysts have lowered their price targets for OrthoPediatrics by a wide margin, with several firm targets now in the $18 to $34 range. They cite recent revenue shortfalls and a more cautious growth outlook, despite continued confidence in the company's long-term fundamentals.Analyseartikel • Nov 25
OrthoPediatrics (NASDAQ:KIDS) Is Making Moderate Use Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Narrativ-Update • Nov 08
KIDS: Recent Revenue Shortfall Will Set Up Potential Longer-Term Surprise
OrthoPediatrics’ analyst price target has been reduced from approximately $26.29 to $24.14, as analysts cite more conservative revenue growth forecasts and recent performance shortfalls. This adjustment comes despite ongoing long-term confidence in the company’s fundamentals.Narrativ-Update • Oct 25
Expanding Global Reach Will Support Long-Term Outlook Amid Revenue Headwinds
Analysts have lowered their price targets for OrthoPediatrics, with targets dropping by $3 to $12 per share. They cite recent revenue shortfalls and reduced guidance, though many continue to highlight strength in the company’s core business fundamentals and long-term outlook.Narrativ-Update • Oct 11
International Clinic Openings And Product Launches Will Expand Global Reach
OrthoPediatrics’ consensus analyst price target has dropped sharply from approximately $33.86 to $26.29 per share. Analysts cite weaker-than-expected revenues due to challenges in select markets and product categories, although the company continues to demonstrate strength in core business fundamentals.Analyseartikel • Sep 26
Investors Holding Back On OrthoPediatrics Corp. (NASDAQ:KIDS)
You may think that with a price-to-sales (or "P/S") ratio of 2x OrthoPediatrics Corp. ( NASDAQ:KIDS ) is a stock worth...Narrativ-Update • Aug 08
International Clinic Openings And Product Launches Will Expand Global Reach
OrthoPediatrics' valuation outlook is stable, with both the future P/E and net profit margin essentially unchanged, resulting in the consensus analyst price target holding steady at $33.86. What's in the News Expanded the OrthoPediatrics Specialty Bracing division with new clinics in California, Ohio, Colorado, New York, and internationally into Ireland, enhancing presence in key hospitals and entering new markets.Analyseartikel • Apr 08
Is OrthoPediatrics (NASDAQ:KIDS) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Neues Narrativ • Mar 26
Pediatric Orthopedic Bracing Expansion Will Secure Market Leadership
Strategic focus on pediatric specialty bracing and product expansion aims for market dominance, improving EBITDA and future earnings growth.Analyseartikel • Mar 06
OrthoPediatrics Corp.'s (NASDAQ:KIDS) Shares Not Telling The Full Story
There wouldn't be many who think OrthoPediatrics Corp.'s ( NASDAQ:KIDS ) price-to-sales (or "P/S") ratio of 3x is worth...Analyseartikel • Nov 05
Investors Still Waiting For A Pull Back In OrthoPediatrics Corp. (NASDAQ:KIDS)
You may think that with a price-to-sales (or "P/S") ratio of 4x OrthoPediatrics Corp. ( NASDAQ:KIDS ) is a stock to...Analyseartikel • Aug 09
The OrthoPediatrics Corp. (NASDAQ:KIDS) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
Shareholders might have noticed that OrthoPediatrics Corp. ( NASDAQ:KIDS ) filed its quarterly result this time last...Analyseartikel • Aug 02
Shareholders Should Be Pleased With OrthoPediatrics Corp.'s (NASDAQ:KIDS) Price
OrthoPediatrics Corp.'s ( NASDAQ:KIDS ) price-to-sales (or "P/S") ratio of 4.5x may not look like an appealing...Analyseartikel • May 09
OrthoPediatrics Corp. (NASDAQ:KIDS) Just Reported And Analysts Have Been Lifting Their Price Targets
As you might know, OrthoPediatrics Corp. ( NASDAQ:KIDS ) just kicked off its latest quarterly results with some very...Analyseartikel • May 07
OrthoPediatrics (NASDAQ:KIDS) Has Debt But No Earnings; Should You Worry?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analyseartikel • Apr 10
Why Investors Shouldn't Be Surprised By OrthoPediatrics Corp.'s (NASDAQ:KIDS) P/S
With a price-to-sales (or "P/S") ratio of 4.9x OrthoPediatrics Corp. ( NASDAQ:KIDS ) may be sending bearish signals at...Analyseartikel • Dec 20
Why Investors Shouldn't Be Surprised By OrthoPediatrics Corp.'s (NASDAQ:KIDS) P/S
OrthoPediatrics Corp.'s ( NASDAQ:KIDS ) price-to-sales (or "P/S") ratio of 5.5x may look like a poor investment...Analyseartikel • May 05
Getting In Cheap On OrthoPediatrics Corp. (NASDAQ:KIDS) Might Be Difficult
You may think that with a price-to-sales (or "P/S") ratio of 8.4x OrthoPediatrics Corp. ( NASDAQ:KIDS ) is a stock to...Aktionärsrenditen
| KIDS | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | 1.9% | -1.3% | 0.7% |
| 1Y | -7.1% | -18.6% | 20.6% |
Rendite im Vergleich zur Industrie: KIDS übertraf die Branche US Medical Equipment , die im vergangenen Jahr eine Rendite von -18.6 erzielte.
Rendite vs. Markt: KIDS hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 20.6 erzielte.
Preisvolatilität
| KIDS volatility | |
|---|---|
| KIDS Average Weekly Movement | 6.5% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiler Aktienkurs: KIDS hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: KIDSDie wöchentliche Volatilität (7%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2006 | 602 | David Bailey | www.orthopediatrics.com |
OrthoPediatrics Corp. ist ein Medizintechnikunternehmen, das anatomisch geeignete Implantate, Instrumente und spezielle Zahnspangen für Kinder mit orthopädischen Erkrankungen in den Vereinigten Staaten und international entwickelt und vertreibt. Das Unternehmen bietet Produkte für die pädiatrische Trauma- und Deformitätenkorrektur, Skolioseverfahren für die Behandlung von Wirbelsäulendeformitäten bei Kindern sowie Sportmedizin und andere Produkte an. Die Produkte des Unternehmens umfassen PediLoc, PediPlates, kanülierte Schrauben, PediFlex-Nagel, PediNail, PediLoc Tibia, ACL-Rekonstruktionssystem, verriegelbare kanülierte Klinge, verriegelbarer proximaler Femur, Spica-Tische, RESPONSE Spine, BandLoc, pädiatrische Nagelplattform | Femur, Devise Rail, Orthex, das Fassier-Duval Telescopic Intramedullary System, der SLIM-Nagel, der GAP-Nagel, das Free Gliding SCFE Screw System, das GIRO Growth Modulation System, das PNP Tibia System, das ApiFix Mid-C System, Mitchell Ponseti, VerteGlideTM, und Boston Brace 3D.
OrthoPediatrics Corp.'s Grundlagenzusammenfassung
| KIDS grundlegende Statistiken | |
|---|---|
| Marktanteil | US$519.61m |
| Gewinn(TTM) | -US$39.68m |
| Umsatz(TTM) | US$243.30m |
2.1x
Kurs-Umsatz-Verhältnis-13.2x
Kurs-Gewinn-Verhältnis Ist KIDS zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| KIDS Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$243.30m |
| Kosten der Einnahmen | US$65.51m |
| Bruttogewinn | US$177.79m |
| Sonstige Ausgaben | US$217.47m |
| Gewinn | -US$39.68m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -1.54 |
| Bruttomarge | 73.07% |
| Nettogewinnspanne | -16.31% |
| Schulden/Eigenkapital-Verhältnis | 30.3% |
Wie hat sich KIDS auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/10 21:33 |
| Aktienkurs zum Tagesende | 2026/07/10 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
OrthoPediatrics Corp. wird von 11 Analysten beobachtet. 9 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Michael Gorman | BTIG |
| Caitlin Cronin | Canaccord Genuity |
| David Turkaly | Citizens JMP Securities, LLC |